Therorna Inc. will present preclinical and pipeline data at the 2026 American Society of Gene & Cell Therapy Annual Meeting, led by TI-0032, its CD19-targeted circular RNA-based in vivo CAR-T candidate that has entered a first-in-human investigator-initiated study in recurrent and refractory autoimmune diseases. The Beijing and Shanghai-based biotechnology company is also highlighting a circular RNA-encoded CD19×CD3 T-cell engager and TI-0093, its HPV16 therapeutic cancer vaccine, as it seeks to position circular RNA as a broader therapeutic platform rather than a single-program technology.
Why Therorna’s TI-0032 could matter for the next phase of in vivo CAR-T therapy
The key strategic signal from Therorna’s ASGCT package is not simply that another CAR-T candidate has reached early human testing. It is that TI-0032 is being advanced as an in vivo CAR-T approach using circular RNA, a format intended to reprogram T cells inside the body rather than through the complex ex vivo manufacturing process that has defined the first generation of CAR-T therapies. That shift matters because conventional autologous CAR-T has demonstrated powerful clinical effects, particularly in hematologic cancers, while also exposing the operational limits of individualized cell collection, engineering, release testing, logistics, and treatment-center capacity.
Therorna is using TI-0032 to test whether circular RNA can help solve part of that scalability puzzle. The candidate is designed as a re-dosable, off-the-shelf therapy that delivers a CD19-directed CAR payload through a T cell-targeted lipid nanoparticle system. In practical terms, the concept is to create transient but durable enough CAR expression in patient T cells without removing and engineering those cells externally. If this model works in humans, it could push CAR-T from a specialized procedure toward a repeatable therapeutic modality. However, that remains the biggest unresolved question. Preclinical depletion of B cells and early clinical initiation are meaningful milestones, but the field will need human safety, pharmacodynamic consistency, immune monitoring, and durability data before the model can be judged against established cell therapy standards.
How circular RNA could change the risk-benefit equation for autoimmune cell therapy
CD19 has become an increasingly important target beyond oncology because B-cell depletion is a validated strategy across several autoimmune disease settings. Conventional anti-CD20 antibodies already play a role in B-cell-driven conditions, while autologous CAR-T has generated interest for severe autoimmune diseases because of its potential to achieve deeper immune reset. Therorna’s TI-0032 sits at the intersection of those two worlds, aiming for a cell therapy-like mechanism without the heavy infrastructure burden of individualized CAR-T manufacturing.
The circular RNA component is central to the proposition. Circular RNA is designed to support protein expression while avoiding some limitations associated with linear RNA stability. Therorna’s preclinical package indicates durable CAR expression in primary human T cells, strong CD8-positive selectivity in the CAR-positive population, and efficient B-cell cytotoxicity at low doses. Those data are important because autoimmune use cases may require a different tolerance for safety and repeat dosing than late-line oncology. A patient with refractory autoimmune disease may benefit from deep B-cell depletion, but clinicians will scrutinize cytokine release, off-target immune activation, infection risk, retreatment feasibility, and recovery dynamics very differently than in aggressive cancer settings.
That distinction creates both opportunity and pressure. If TI-0032 can provide controlled, redosable B-cell depletion with a manageable immune safety profile, it could offer a differentiated profile in autoimmune therapy. If the treatment produces unpredictable T-cell transduction, excessive immune activation, or inconsistent depletion across tissues, the off-the-shelf promise may be outweighed by safety complexity. The first-in-human study therefore becomes less about proving circular RNA can express a CAR and more about showing that in vivo engineering can be clinically controllable.
Why the targeted lipid nanoparticle system may be as important as the circRNA payload itself
Therorna’s platform narrative rests on circular RNA, but the delivery system may ultimately determine whether TI-0032 can succeed. The candidate uses a T cell-targeted lipid nanoparticle approach with a humanized antibody fragment for site-directed conjugation and an ionizable lipid designed to avoid hepatic accumulation. That is a critical detail because many RNA delivery systems have historically favored liver uptake, which is useful for hepatology or systemic protein production but less suitable when the goal is selective immune-cell engineering.
The value of targeted delivery lies in reducing unwanted expression and improving dose efficiency. Therorna’s preclinical findings in humanized mouse models and non-human primates suggest activity across blood and tissue compartments, including complete B-cell depletion in multiple immune-relevant sites. For an autoimmune therapy, tissue distribution could matter because disease activity is not always reflected by peripheral blood markers alone. The ability to affect lymphoid tissues, bone marrow, or disease-relevant immune reservoirs may influence depth and durability of response.
However, targeted LNP delivery is still an emerging frontier, and this is where regulators and clinicians are likely to focus closely. The same features that make targeted delivery attractive also create new questions around biodistribution, repeat dosing immunogenicity, antibody fragment behavior, complement activation, and manufacturing reproducibility. In vivo CAR-T is not only a drug product. It is also a transient engineering system introduced into a biologically complex environment. That means the delivery platform must be evaluated with the same seriousness as the CAR construct itself.
What Therorna’s broader ASGCT pipeline reveals about its platform strategy
Therorna is not presenting TI-0032 in isolation. The ASGCT lineup also includes a circular RNA-encoded CD19×CD3 T-cell engager and TI-0093, a circular RNA-based HPV16 therapeutic cancer vaccine. This is strategically important because it suggests Therorna is trying to build a multi-platform circular RNA business across in vivo cell therapy, in-body biologics, and therapeutic vaccines. That breadth may appeal to investors and partners looking for platform leverage, but it also raises execution risk.
The CD19×CD3 T-cell engager concept is especially relevant because it offers another route to B-cell depletion in autoimmune disease. Instead of engineering T cells with a CAR, the therapy is designed to enable in-body production of a bispecific engager that directs T cells toward CD19-positive cells. If successful, that approach could compete with or complement CAR-T strategies by offering a different balance of exposure, reversibility, and immune activation. The unresolved issue is whether circular RNA expression can generate a therapeutic window that is long enough to be useful but controllable enough to avoid prolonged toxicity.
TI-0093 expands the story into oncology vaccines, targeting HPV16-positive solid tumors. Therapeutic cancer vaccines have long faced challenges around immune potency, tumor microenvironment resistance, antigen selection, and clinical endpoint translation. Therorna’s HPV16 program may benefit from a biologically defined viral antigen target, but the commercial and clinical path remains demanding. The broader takeaway is that Therorna is using circular RNA not as a single asset wrapper but as a modular expression technology. That is ambitious, but it will require each modality to prove its own clinical logic rather than relying on platform enthusiasm alone.
Why regulatory clarity will be a major test for circRNA-based in vivo therapies
Therorna has indicated that a dual United States and China IND filing for TI-0032 remains on track. That cross-border regulatory plan is noteworthy because in vivo CAR-T using circular RNA combines multiple areas of regulatory scrutiny, including RNA product characterization, lipid nanoparticle delivery, immune-cell targeting, CAR expression, and autoimmune disease trial design. Each of those areas has its own precedent. The combination, however, remains novel.
Regulators are likely to examine dose escalation, immune monitoring, persistence of CAR expression, vector or payload clearance, B-cell recovery, cytokine signals, tissue biodistribution, and repeat-dose safety. For autoimmune disease, trial design will also need to justify endpoints that move beyond short-term B-cell depletion. Clinical benefit, steroid sparing, flare reduction, biomarker normalization, patient selection, and durability of remission will matter if the program progresses beyond early proof of mechanism.
The first-in-human investigator-initiated study gives Therorna a clinical starting point, but it does not remove the need for rigorous controlled development. Early autoimmune CAR-T data across the field have generated excitement, yet the challenge is to convert mechanistic promise into reproducible benefit in broader patient populations. The strongest version of the TI-0032 thesis is that circular RNA and targeted LNPs can make immune-cell reprogramming more scalable. The hardest part will be proving that scalability does not come at the cost of precision, safety, or durability.
What clinicians and industry observers will watch after Therorna’s ASGCT presentations
The next important readouts for Therorna will not be limited to whether TI-0032 depletes B cells in humans. Clinicians will want to see how quickly depletion occurs, how deeply it reaches relevant compartments, how long the effect lasts, and whether immune recovery is predictable. They will also look for early signals of cytokine release, neurotoxicity, infection risk, cytopenias, and immunogenicity linked to repeat dosing. For autoimmune disease specialists, the essential question is whether the treatment can offer meaningful disease control without creating an unacceptable long-term immune suppression burden.
Industry observers will also watch manufacturing and comparability. A therapy positioned as off-the-shelf needs strong batch consistency, scalable production, stable formulation, and clear release criteria. Therorna’s in-house GMP capability gives the biotechnology firm an operational foundation, but commercial-scale manufacturing is a different challenge from producing early clinical batches. If the platform progresses, the ability to scale targeted LNP production with reproducible potency will become a core competitive factor.
Therorna’s ASGCT data therefore mark an important platform moment, but not a final validation moment. The biotechnology firm has moved circular RNA into a high-value and high-scrutiny area of cell therapy innovation. TI-0032 could become a defining test of whether in vivo CAR-T can move from compelling concept to clinically usable autoimmune treatment. For now, the promise is clear, the science is provocative, and the burden of proof has only just begun to rise.
